Trial · NCT02014519
Outcomes37
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 37
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Seronegative Subjects in Terms of Anti-PT Concentrations | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Age) | At the time of enrollment of each subject (Day 0). | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Age) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Age) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Age) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Gender) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available and who provided information on recent history of long-lasting cough. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available and who provided information on recent history of long-lasting cough. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available and who provided information on recent history of long-lasting cough. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available and who provided information on recent history of long-lasting cough. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Smoking Status) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Smoking Status) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Smoking Status) | At the time of enrollment of each subject (Day 0) | The analysis was performed on the According-to-Protocol (ATP) cohort included all evaluable subjects for whom valid laboratory test results for anti-pertussis toxin antibodies were available. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02014519/outcomes